Denmark · Delayed Price · Currency is DKK Novozymes Statistics
Total Valuation
Novozymes has a market cap or net worth of DKK 183.66 billion. The enterprise value is 205.23 billion.
| Market Cap | 183.66B |
| Enterprise Value | 205.23B |
Important Dates
The next confirmed earnings date is Thursday, August 20, 2026.
| Earnings Date | Aug 20, 2026 |
| Ex-Dividend Date | Mar 24, 2026 |
Share Statistics
Novozymes has 465.91 million shares outstanding. The number of shares has increased by 60.87% in one year.
| Current Share Class | 412.17M |
| Shares Outstanding | 465.91M |
| Shares Change (YoY) | +60.87% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 26.38% |
| Float | 346.58M |
Valuation Ratios
The trailing PE ratio is 41.25 and the forward PE ratio is 24.15. Novozymes's PEG ratio is 3.49.
| PE Ratio | 41.25 |
| Forward PE | 24.15 |
| PS Ratio | 5.85 |
| PB Ratio | 2.25 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 29.30 |
| P/OCF Ratio | 19.17 |
| PEG Ratio | 3.49 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.83, with an EV/FCF ratio of 32.74.
| EV / Earnings | 46.02 |
| EV / Sales | 6.54 |
| EV / EBITDA | 17.83 |
| EV / EBIT | 28.81 |
| EV / FCF | 32.74 |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.29.
| Current Ratio | 1.67 |
| Quick Ratio | 1.02 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 2.08 |
| Debt / FCF | 3.83 |
| Interest Coverage | 16.65 |
Financial Efficiency
Return on equity (ROE) is 5.39% and return on invested capital (ROIC) is 5.53%.
| Return on Equity (ROE) | 5.39% |
| Return on Assets (ROA) | 3.80% |
| Return on Invested Capital (ROIC) | 5.53% |
| Return on Capital Employed (ROCE) | 6.27% |
| Weighted Average Cost of Capital (WACC) | 6.93% |
| Revenue Per Employee | 2.83M |
| Profits Per Employee | 401,849 |
| Employee Count | 11,263 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 2.43 |
Taxes
In the past 12 months, Novozymes has paid 1.19 billion in taxes.
| Income Tax | 1.19B |
| Effective Tax Rate | 21.03% |
Stock Price Statistics
The stock price has decreased by -16.71% in the last 52 weeks. The beta is 0.62, so Novozymes's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -16.71% |
| 50-Day Moving Average | 381.76 |
| 200-Day Moving Average | 390.13 |
| Relative Strength Index (RSI) | 60.79 |
| Average Volume (20 Days) | 659,557 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novozymes had revenue of DKK 31.39 billion and earned 4.46 billion in profits. Earnings per share was 9.56.
| Revenue | 31.39B |
| Gross Profit | 17.53B |
| Operating Income | 7.17B |
| Pretax Income | 5.65B |
| Net Income | 4.46B |
| EBITDA | 11.56B |
| EBIT | 7.17B |
| Earnings Per Share (EPS) | 9.56 |
Balance Sheet
The company has 2.45 billion in cash and 24.01 billion in debt, with a net cash position of -21.56 billion or -46.28 per share.
| Cash & Cash Equivalents | 2.45B |
| Total Debt | 24.01B |
| Net Cash | -21.56B |
| Net Cash Per Share | -46.28 |
| Equity (Book Value) | 81.61B |
| Book Value Per Share | 176.26 |
| Working Capital | 6.15B |
Cash Flow
In the last 12 months, operating cash flow was 9.58 billion and capital expenditures -3.31 billion, giving a free cash flow of 6.27 billion.
| Operating Cash Flow | 9.58B |
| Capital Expenditures | -3.31B |
| Depreciation & Amortization | 4.39B |
| Net Borrowing | 11.09B |
| Free Cash Flow | 6.27B |
| FCF Per Share | 13.45 |
Margins
Gross margin is 55.86%, with operating and profit margins of 22.84% and 14.21%.
| Gross Margin | 55.86% |
| Operating Margin | 22.84% |
| Pretax Margin | 17.99% |
| Profit Margin | 14.21% |
| EBITDA Margin | 36.83% |
| EBIT Margin | 22.84% |
| FCF Margin | 19.97% |
Dividends & Yields
This stock pays an annual dividend of 6.50, which amounts to a dividend yield of 1.65%.
| Dividend Per Share | 6.50 |
| Dividend Yield | 1.65% |
| Dividend Growth (YoY) | 4.84% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 111.92% |
| Buyback Yield | -60.87% |
| Shareholder Yield | -59.22% |
| Earnings Yield | 2.43% |
| FCF Yield | 3.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Novozymes is 460.94, which is 16.93% higher than the current price. The consensus rating is "Buy".
| Price Target | 460.94 |
| Price Target Difference | 16.93% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | 6.98% |
| EPS Growth Forecast (3Y) | 8.79% |
Stock Splits
The last stock split was on November 28, 2011. It was a forward split with a ratio of 5.
| Last Split Date | Nov 28, 2011 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Novozymes has an Altman Z-Score of 4.19 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.19 |
| Piotroski F-Score | 6 |